Viscosupplementation: Techniques, indications, results  by Legré-Boyer, V.
RV
V
a
b
c
A
A
K
V
H
O
C
H
S
1
h
o
u
b
k
c
t
O
7
1Orthopaedics & Traumatology: Surgery & Research 101 (2015) S101–S108
Available  online  at
ScienceDirect
www.sciencedirect.com
eview  article
iscosupplementation:  Techniques,  indications,  results
.  Legré-Boyera,b,c,∗
Institut de l’Appareil Locomoteur Nollet, 23, rue Brochant, 75017 Paris, France
Service de Rhumatologie, Hôpital Universitaire Pitié-Salpêtrière, 72013 Paris, France
Hôpital américain de Paris, 92200 Neuilly-sur-Seine, France
a  r  t  i  c  l e  i  n  f  o
rticle history:
ccepted 10 July 2014
eywords:
iscosupplementation
yaluronic acid
steoarthritis
hondropathy
ylan
odium hyaluronate
a  b  s  t  r  a  c  t
Viscosupplementation  by  hyaluronic  acid  (HA)  injections  is  frequently  used  for  local  treatment  of
osteoarthritis  (OA),  due  to ease  of  use  and  good  tolerance.  A profusion  of  linear  or reticulated  HA  derivates
are marketed,  with  varied  characters  and  levels  of evidence.  Viscosupplementation  has  demonstrated
moderate  but  signiﬁcant  efﬁcacy  (20%)  versus  placebo  in  terms  of pain  and function,  with  a high  rate
of  responders  (60–70%)  in  knee  osteoarthritis.  It allows  reduced  administration  of opioid  analgesics  and
NSAIDs,  with  improved  risk/beneﬁt  ratio,  and  may  delay  joint  replacement.  Cartilage  protection  remains
to  be proven.  Clinical  efﬁcacy  shows  1–4  weeks’  later  onset  than  corticosteroids,  but is  maintained  for
6  or even  12  months.  Systematic  association  of  corticosteroid  and HA  injection  is  not  justiﬁed,  and  an
interval  has  to  be left before  undertaking  arthroplasty.  Intra-articular  injection  of  HA requires  a  skilled
specialist,  and  may  be difﬁcult  in a non-swollen  joint;  some  tips and  tricks  may  be helpful.  In  other  joints
than  the  knee,  radiologic  or ultrasound  guidance  is recommended.  The  efﬁcacy  of  viscosupplementation
is  a matter  of ongoing  debate,  after  discordant  ﬁndings  in  some  meta-analyses.  Some  poor  results  may
be  due  to inappropriate  use  of  HA  injections,  poorly  adapted  to  the  patient’s  OA phenotype.  Viscosupple-
mentation  is  a treatment  for  chronic  moderate  symptomatic  OA,  and  not  for ﬂares  with  joint  swelling.
Application  in sport-related  chondropathy  has  yet  to be  properly  assessed.  The  optimal  response  pro-
ﬁle  remains  to  be determined.  The  ideal indication  in  the  knee  seems  to be moderate  femorotibial  OA
without  swelling.  Results  have  been  generally  disappointing  in  hip  osteoarthritis  but  promising  in OA
of  the  ankle  and  shoulder  (with and  without  rotator  cuff  tear).  Further  studies  are  needed  to determine
response  proﬁle  and  optimal  treatment  schedule,  according  to  the  joint.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Viscosupplementation, consisting in intra-articular injection of
yaluronic acid (HA) derivatives, is the main local treatment in
steoarthritis (OA) along with corticosteroid injection. It has been
sed in humans for more than 30 years, mainly in OA of the knee
ut increasingly in other joints.
A very large number of clinical trials have been performed; in
nee OA, several meta-analyses gave discordant results, sparking
ontroversy around the efﬁcacy of the technique.
The present update aims to determine good practice and indica-
ions for viscosupplementation as local treatment for symptomatic
A, so as to optimize efﬁcacy.
∗ Correspondence. Institut de l’Appareil Locomoteur Nollet, 23, rue Brochant,
5017 Paris, France. Tel.: +33 6 13 60 09 36; fax: +33 1 47 27 08 76.
E-mail address: virginlegr@aol.fr
http://dx.doi.org/10.1016/j.otsr.2014.07.027
877-0568/© 2014 Elsevier Masson SAS. All rights reserved.1.1. Action of intra-articular HA injection [1]
HA, the main constituent of cartilage and synovial ﬂuid, is a long
polysaccharide (glycosaminoglycan) chain, with a hydrophilicity
that gives it the viscoelastic properties underlying the mechanical
properties of cartilage (shock absorption) and synovial ﬂuid (joint
lubrication, cartilage protection).
OA involves qualitative and quantitative HA deﬁciency: mean
molecular weight (MW),  corresponding to chain length, is 4–5 mD
in the healthy joint and 2–4 mD in OA, with concentration halved.
Injecting exogenous HA into the joint is intended not only
to restore the mechanical properties of the cartilage and syno-
vial ﬂuid, but also to achieve certain biological effects. The HA is
taken up by speciﬁc joint receptors, providing numerous beneﬁcial
effects: moderate anti-inﬂammatory action, reduced cytokine-
induced enzyme production, anti-oxidant action, anabolizing effect
on cartilage, and direct analgesia by masking the joint nociceptors.
Its visco-inductive properties (synoviocyte-mediated stimula-
tion of endogenous HA production) could account for the prolonged
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Table 1
Hyaluronic acid forms available in France in 2014.
Hyaluronic acid Forms
Linear HA Sodium hyaluronate: (MW  0.5–3 mD)
Multi-injection: Adant® , Arthrum® , Euﬂexxa® , Go-on® ,
Hyalgan® , Orthovisc® , Ostenil® , Sinovial® ,
Structovial® , Synocrom®
Single-injection: Arthrum monodose® , Coxarthrum® ,
Synochrom forte®
Reticulated HA (MW > 3 mD)
Hylan GF-20: Synvisc® , Synvisc one®
Sodium hyaluronate: Monovisc® , Synocrom forte one®
happycross
NASHA: Durolane®
Combined HA Single-injection
Mannitol: Ostenil plus® Happyvisc® , Happycross®
Chondroitine sulfate: Arthrum HCS® , Synovium
surgical®
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Fig. 1. Usual HA injection technique in non-swollen knee. Introduction of 21-gauge
needle by lateral lateropatellar approach (1–2 cm below and down from the super-
olateral edge of the patella, knee in extension or slight ﬂexion, quadriceps relaxed).
Prior lateral subluxation of the patella, imposed by the other hand, facilitates the
sensation of capsule passage. Attempted synovial ﬂuid aspiration. Then injection of
2–6  ml  HA without resistance or pain. Withdrawal of needle and mobilization ofASHA: non-animal stabilized hyaluronic acid.
fﬁcacy of injected exogenous HA despite its short joint residence
ime, as it is rapidly degraded after injection.
.2. What forms of HA are available in France?
In France, more than 12 HA derivatives are on the market, clas-
iﬁed as “devices”, except in the case of Hyalgan®, which counts as
 drug with market authorization in knee OA.
Two groups can be distinguished (Table 1): low-MW linear HA;
nd reticulated HA (3-dimensional structure of linked HA chains),
ith higher MW and probably slower degradation and longer joint
esidence, often administered as a single-injection.
Low-dose (1 ml)  preparations are available for small joints.
Preparations with associated adjuvants (mannitol, sorbitol,
hondroitin sulfate), reticulated or not, have come onto the market
ore recently, with the aim of prolonging joint residence, although
his has not been demonstrated.
HA derivatives differ not only in reticulation and MW (chain
ength) but also in origin (avian: cockscomb; synthetic: bacte-
ial fermentation), sterilization process (heat or ultra-ﬁltration),
onditioning (2–6 ml  syringes) and validation on high-quality ther-
peutic trials.
The reference forms, which have been the focus of most studies,
re Hyalgan® for linear HA and Synvisc® for reticulated HA. The
linical impact of the various characteristics of HA remains unclear,
nd no product can be clearly recommended over another.
. Technique
Injection technique is of prime importance for both efﬁcacy and
olerance. Injection must be strictly intra-articular, which is not
asy to ensure in non-swollen joints, which are the main indication
or viscosupplementation.
In the knee, 10–30% of injections performed by senior physicians
re known to be defective [2]. A lateral lateropatellar approach has
een shown to be clearly preferable; anterior approaches show high
ates of failure and poor tolerance. Local reaction rates of up to 30%
ave been found for anteromedial injection [3].
In the hip, shoulder and thumb joints, success is even less sure,
nd radiologic guidance is recommended..1. General rules for injection
The classic technique for HA knee injection is presented in Fig. 1.
The general procedure is as follows:knee in ﬂexion-extension.
• relevant personalized prior information to patient;
• asepsis as in joint corticosteroid inﬁltration. Certain HA deriva-
tives, like ready-to-use corticosteroid syringes, do not have sterile
exterior conditioning (outer surface of syringe) and this is to be
borne in mind;
• choice of appropriate approach according to joint;
• appropriate needle caliber (21-gauge for reticulated derivatives);
• aspiration of any synovial ﬂuid;
• injection without resistance or pain;
• joint mobilization after injection;
• record of HA batch number;
• 24 hours’ relative rest (no sports, no effort with the limb).
2.2. Tricks and tips
Some tricks and tips may  be useful in difﬁcult cases: obesity,
postoperative ﬁbrosis, severe femoropatellar OA, etc.:
• the back-ﬂow technique (Fig. 2), which we developed and val-
idated for the knee, provides very precise injection, with the
needle positioned intra-articularly in 100% of cases when back-
ﬂow is clearly obtained [4]. The method can be applied in other
joints, notably the ankle, although not yet validated;
• the “squishing sound” conﬁrms that injection has been successful.
It can be heard in passive ﬂexion-extension of the knee after injec-
tion of an HA derivative with air-bubble once the needle has been
withdrawn. This frequently employed test has been validated [5],
but is just a retrospective check, as it requires the substance to
have been actually injected;
• in some less easily accessible joints (hip, shoulder, thumb), radio-
scopic guidance with a small injection of contrast medium (Fig. 3)
or ultrasound guidance is recommended. Ultrasound has advan-
tages: with no radiation and no risk of allergic reaction, it detects
deep effusion; however, it requires a trained operator and special
asepsis.
V. Legré-Boyer / Orthopaedics & Traumatology: S
Fig. 2. Back-ﬂow technique. Presumed intra-articular needle positioning. Injection
of 0.5 ml  xylocaine 0.5% (or physiological saline), checking the slightest resistance.
Withdrawal of syringe (needle remaining inside the joint), and observation of onset
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if  back-ﬂow through the needle. If there is clear back-ﬂow, HA can be injected; if
ot,  the procedure is repeated (maximum 3 cc xylocaine).
If a local intra-articular anesthetic is to be used, lidocaine should
e low-dose and low-concentration (0.5%) because of its bacterio-
tatic and possible chondrotoxic effects.
.3. Administration schedules
Viscosupplementation comprises 1 to 5 injections at 1–4 week
ntervals.
Dose depends on the form of HA (linear or reticulated) and the
oint, as joint capacity varies.
In knee OA, a series of 3 injections are performed at 1-week
ntervals; alternatively, a single-injection may  be made.
In joints other than the knee, the procedure is not well codiﬁed.
e suggest a schedule based on the data of the literature (Table 2).
Single-injection schedules are attracting growing interest. These
ften involve reticulated HA derivatives which should have longer
oint residence. Reducing the number of injections reduces the risk
f infection and, in patients under anticoagulants, the risk of hem-
rrhage.
ig. 3. Radioscopy-guided HA injection to hip. Needle positioning on anterolateral
pproach under radioscopy. Injection of a small amount of iodine-based contrast
edium. Once the arthrogram obtained, attempted synovial ﬂuid aspiration. Then
njection of 2–4 ml  HA.urgery & Research 101 (2015) S101–S108 S103
2.4. Attitude in case of joint effusion
Synovitis should be treated in priority before HA injection: rest,
joint ice treatment, NSAIDs and, if necessary, puncture and corti-
costeroid inﬁltration. HA injection will then be postponed for 1–4
weeks.
2.5. Can corticosteroids be associated to HA in the same injection?
The association, in the ﬁrst of the 3 injections or in a single-
injection, may be considered, especially in case of severe pain or
persistent effusion. Systematic association, on the other hand, is
not justiﬁable, especially in non-swollen knee, as clinical bene-
ﬁt lasts no more than a week [6], and the risks associated with
corticosteroid injection are non-negligible.
In patients awaiting arthroplasty, an interval of more than
6 weeks (12–24 weeks in our practice, depending on the form of
corticosteroid) should be left between the last injection and the
arthroplasty surgery, to limit the risk of implant infection [7]. Con-
cerning HA, no study has yet been done, but we  consider that a 4
weeks interval before arthroplasty is safe, regarding to the absence
of local immunosuppressive effect of HA.
3. Indications
3.1. General indications
Viscosupplementation is classically implemented in OA, on
condition that the OA is symptomatic, that medical treatment
(non-pharmacologic, analgesics, NSAIDs) has failed or induced
intolerance, and that there is no acute inﬂammation (i.e., no severe
effusion).
National health insurance cover in France currently applies only
to knee OA, and not other locations, and includes most HA deriva-
tives, at a rate of 1 treatment per year per knee, on condition that
the OA is painful and resistant to medical treatment and that the
HA is prescribed and administered by a specialist (rheumatologist,
physical and rehabilitation physician or orthopedic surgeon).
HA used to have an integral role in international guidelines for
knee, hip and thumb OA, including the European League Against
Rheumatism (EULAR) guidelines, in which HA injection was recog-
nized as having real if moderate impact on symptoms [8].
The role of viscosupplementation was, however, questioned
recently by most international scientiﬁc societies in updates to their
guidelines for knee OA treatment [9–12] (Table 3):
• according to the Osteoarthritis Research Society International
(OARSI), the recommendation of HA is “uncertain” in isolated
knee OA and “not appropriate” in polyarthritis [9]. Despite the
lack of any real analysis of adverse effects in the literature, the
OARSI experts considered (as “expert opinion”) that risk is greater
with HA injection than corticosteroid inﬁltration or NSAIDs; this
opinion is highly questionable;
• the American College of Rheumatology (ACR) revised its guide-
lines in 2012 [10]: the experts laid down no general guidelines
for HA in knee OA, but did recommend its use in case of medi-
cal failure, especially in over 75 year olds. Their position was the
same regarding hip OA;
• the American Academy of Orthopaedic Surgeons (AAOS) [11] and
British National Institute for Health and Care Excellence (NICE)
[12] do not recommend HA in knee OA.
Viscosupplementation is not indicated for preventive purposes,
no chondroprotective effect having been demonstrated in human
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Table 2
Technical characteristics of HA injection according to joint.
Knee Hip Shoulder Ankle Metacarpophalangial
Approach Lateral
lateropatellar
Anterior or
anterolateral
Anterior
(radioscopy) or
posterior (US)
Anteromedial
or anterior
Lateral
Guidance No
Except difﬁcult
cases
Radioscopy or
US
Radioscopy >
US
NO
Or radioscopy
> US
Radioscopy or
US
Quantity per
injection
2–6 ml  (single-
injection)
2–4 ml  2–4 ml  2–3 ml  0.5–1 ml
Schedule 3  injections (1 2–3 injections 1–3 injections 3 injections (1 1–3 injections
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per week) or
single-injection
(1 per month)
or
single-injection
linical studies. It is reserved to symptomatic OA. Yearly renewal is
ndicated only if symptoms recur.
According to the scientiﬁc societies, who found OA therapy on a
ombination of pharmacologic and non-pharmacologic treatments
8], viscosupplementation should be utilized in conjunction with:
non-pharmacologic modalities (counseling on weight reduction,
physical activity and joint sparing and stabilization, and orthoses)
possibly other drugs.
.2. Indications according to OA phenotype
OA characteristics vary from patient to patient and may  affect
he efﬁcacy of viscosupplementation. It is difﬁcult to predict the
ype of responder, as studies do not often take account of phenotype
n interpreting results. Certain trends, however, seem to emerge:
.2.1. Severity of radiologic joint space narrowing
Moderate OA is the indication of choice for viscosupplemen-
ation, efﬁcacy being better in moderate joint space narrowing
Kellgren and Lawrence grades II and III), whichever the joint. Some
tudies, however, have reported efﬁcacy in highly advanced knee
A (grade IV), in which HA injection can provide interim relief
waiting arthroplasty [3,13]. Advanced hip OA, on the other hand,
oes not respond to viscosupplementation, and treatment is arthro-
lasty.
.2.2. Compartmental location
In the knee, the ideal indication is femorotibial OA. In less severe
emoropatellar OA, viscosupplementation appeared less effective
n an open British study, with a response rate of around 50% [14],
s observed in clinical practice.
.2.3. Inﬂammatory ﬂare of OA
In acute inﬂammation, with severe effusion, viscosupplementa-
ion is not indicated. Synovitis has been shown to be associated with
ccelerated joint cartilage degradation [2]. Moreover, it impairs the
fﬁcacy of HA, less by dilution in the effusion ﬂuid than due to
able 3
ecommendations for intra-articular HA injections in International knee OA guidelines.
Scientiﬁc society 
EULAR (2003) European League Against Rheumatism 
ACR  (2014) American College of Rheumatology 
AAOS (2013) American Association of Orthopaedic Surgeons 
NICE  (2014) National Institute for Health and Clinical Excellen
OARSI (2014) Osteoarthritis Research Society International (1 per week or
per month)
per week) (1 per week or
per month)
enzymes and oxidants (hyaluronidases, free radicals) degrading the
HA chains. The acute episode should be treated in priority (NSAIDs,
corticosteroids) and HA treatment postponed.
3.2.4. OA with subchondral bone lesions
Acute intense mechanical pain with extensive bone edema, bone
ﬁssure or stress necrosis on MRI  does not respond to HA and
should be managed by non-weight-bearing [2], viscosupplemen-
tation being postponed.
3.2.5. OA associated with other lesions
Certain lesions (unstable meniscal tear, ligament laxity, limb
malalignment, etc.) need to be taken into account and treated in
parallel to viscosupplementation, as they are aggravation factors of
OA. In case of conservative surgery (osteotomy, ligamentoplasty,
arthroscopic treatment of meniscal lesions, femoroacetabular
impingement, osteochondral lesions of the talus (OLT), etc.), HA
injection may  be performed secondarily, some weeks after surgery,
if pain persists. Systematic HA injection at end of surgery cannot
be recommended, being poorly assessed and showing only very
short-term beneﬁt in the few published studies.
3.2.6. Radiologic chondrocalcinosis
Chondrocalcinosis is extremely frequent in elderly patients, but
is not a contraindication for HA injection, on condition that there
is no gout-like acute inﬂammation of the knee [15]. According to
some reports, it is actually a factor of good response to HA [16]. The
injection technique should be non-traumatic with regard to the
cartilage, to avoid crystal release inducing a micro-crystalline ﬂare.
Preventive NSAID treatment during the days following injection is
optional.3.3. Indications in athletes
HA is recognized to be non-doping, making it an interesting
adjuvant option for athletes.
HA guidelines
Recognized efﬁcacy as slow-action treatment in
symptomatic OA
No general recommendation
Conditional recommendation: treatment resistance,
elderly subject
Not recommended
ce Not recommended
Uncertain recommendation in isolated knee OA
Not appropriate in polyarthritis OA
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Table  4
Indications for viscosupplementation according to symptomatic joint.
Ideal indication Possible indications No indication
Knee Moderate femorotibial OA without effusion Chondropathy
Femoropatellar OA
Advanced knee OA
Hip  Moderate hip OA without effusion, not hip
replacement candidate
Dysplasia (femoroacetabular impingement
etc.)
Advanced hip OA
Rapidly destructive hip OA
Shoulder Moderate shoulder OA with or without cuff
tear
Isolated cuff tear
Capsulitis
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eAnkle  Moderate talocrural OA without effusion
Hand  Moderate thumb OA resistant to
corticosteroids
In knee OA with radiologic signs in athletes, indications follow
eneral guidelines, with viscosupplementation scheduled if possi-
le out of season and adapting the patient’s sports activity.
In infra-radiologic chondropathy (often focal cartilage lesions
etected on MRI, CT arthroscopy or conventional arthroscopy),
hich generally affects younger subjects, rules are poorly deﬁned
or lack of high-quality studies. The efﬁcacy of viscosupplementa-
ion is probable, but has not been properly assessed.
Usual precautions should be taken (post-injection rest,
omplete therapeutic schedule, no preventive injection in asymp-
omatic knee, etc.) despite the pressure brought to bear on both
thlete and physician.
.4. Summary of indications according to joint
Ideal indications with maximal chance of efﬁcacy are basically
oderate OA without effusion or associated lesions (ligamentous,
eniscal, malalignment etc.).
Various speciﬁcities emerge from clinical studies according to
oint (Table 4):
in hip OA, results have generally been disappointing. There would
seem to be no role for HA in advanced or rapidly destructive hip
OA, which require total hip replacement. There are beginning
to be reports of beneﬁt with viscosupplementation in femoroac-
etabular impingement [17];
shoulder OA with or without rotator cuff tear appears to be a good
indication, but not isolated cuff tear or capsulitis;
in the ankle (talocrural joint), a subtalar component in sympto-
matology has ﬁrst to be ruled out, possibly by local anesthetic
test. HA injection may  be useful after arthroscopic treatment of
osteochondral lesions of the talus;
abarticular pathology is beginning to be assessed (trigger ﬁn-
ger, epicondylalgia, ankle sprain, etc.), but there have been no
validation studies.
. Results
.1. Clinical efﬁcacy of viscosupplementation
Many studies have been published, especially on knee OA,
eporting overall positive results on pain and function, while gen-
ine clinical trials have found negative results; this has given rise
o ongoing controversy.
.1.1. Knee OA
More than 100 controlled clinical trials have been published onnee OA, comparing various HA derivatives versus placebo, NSAIDs,
orticosteroid inﬁltration or a reference HA. Most found moderate
fﬁcacy of around 20% versus placebo.
More interesting for clinical practice:Osteochondral lesions of the talus
Trigger ﬁnger
• 60–70% of patients are responders, on the OMERACT-OARSI, PASS
and MCII criteria [13];
• efﬁcacy is delayed but long-lasting. Six-month effect kinetics was
assessed in a meta-analysis of HA versus placebo, measuring
effect size on pain in various time intervals: efﬁcacy became sig-
niﬁcant at 4 weeks, peaked at 8 weeks and persisted for 6 months
[20].
4.1.1.1. HA versus placebo: the controversy. Most studies have been
versus placebo, with sometimes contradictory results. Ten meta-
analyses have been made, mostly positive but three negative,
including Rutges’, which was notably virulent but questionable
[18], raising controversy as to the efﬁcacy of viscosupplementation
and thus of its legitimacy in terms of cost/beneﬁt.
This is why there is a threatened withdrawal of national
health insurance cover in France. Rutges’ meta-analysis was mainly
founded on a negative risk/beneﬁt ratio, which is open to serious
doubt inasmuch as HA shows efﬁcacy that is greater than for anal-
gesics, and equivalent to that of NSAIDs with much better tolerance.
The discordance in ﬁndings between the meta-analyses may
partly be due to their great heterogeneity [13]: they were based
on studies of heterogeneous OA series that took no account of
phenotype (acute inﬂammatory or osseous episode, associated
lesions, etc.). Assessment criteria and statistical methodology var-
ied greatly, affecting interpretation. HA schedules differed: 1, 2, 3
or 5 injections per cycle for 1 to 3 cycles per year. The HA deriva-
tives differed: linear or reticulated, varying MW and concentration.
And ﬁnally, injection techniques were not speciﬁed and quality was
uncertain.
Analysis of these meta-analyses suggests a beneﬁcial, although
slight, effect of HA on pain and function in knee OA [13,19]. In some
studies, efﬁcacy appeared better in certain phenotypes, and notably
moderate OA without effusion.
4.1.1.2. Efﬁcacy of viscosupplementation versus other treatments.
The pain effect size versus placebo is slight (−0.37), but better
than that of paracetamol (−0.20) and comparable to that of NSAIDs
(−0.32) with a better risk/beneﬁt ratio [13].
4.1.1.2.1. Analgesics. Analgesics have ﬁrst-line indication in
OA according to international guidelines [8]. Paracetamol is usu-
ally well tolerated (although digestive toxicity has recently been
highlighted), but efﬁcacy is slight. Opioids show greater analgesic
efﬁcacy (effect size −0.79), but with poor tolerance, especially in
the elderly (risk of falls).
4.1.1.2.2. NSAIDs. Prolonged use of NSAIDs is not recom-
mended, due to digestive, cardiovascular and renal toxicity.
Bannuru’s meta-analysis [21] showed HA to be as effective as
NSAIDs, but with better tolerance, tipping the risk/beneﬁt ratio in
favor of viscosupplementation. There is no advantage in systemat-
ically associating NSAIDS to HA, as this does not improve efﬁcacy.
Thus viscosupplementation seems to be a good alternative to
opioid analgesics and NSAIDs, with a better risk/beneﬁt ratio than
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he latter. It is thus clearly of interest in elderly patients or in case
f multiple pathology and multi-medication.
4.1.1.2.3. Corticosteroid inﬁltration. Although far from being a
ecent therapy, corticosteroids have been the focus of only 7 ran-
omized controlled trials in knee OA, showing slight beneﬁt for
ain over placebo (pain effect size −0.39), comparable to that of
A.
Efﬁcacy kinetics differs: the effect of corticosteroids is fast but
hort (about 1 to 3 weeks), whereas that of HA is delayed but lasts
everal months [20]. This was detailed in a meta-analysis of HA ver-
us corticosteroid inﬁltration in knee OA, analyzing pain effect size
ver time in randomized trials against placebo [22]. Corticosteroid
fﬁcacy was greater at 2 weeks, equivalent at 4 weeks and then
oorer than that of HA at 8, 12 and 26 weeks.
However, it was not speciﬁed whether the patients in these
tudies had joint effusion, which is unfortunate as it could inﬂuence
he efﬁcacy of one or the other treatment.
It may  be wondered whether there is beneﬁt in associating HA
o a local corticosteroid: theoretically, this could accelerate onset
f efﬁcacy, but this failed to be conﬁrmed by the one random-
zed study on the subject: systematic association of a corticosteroid
triamcinolone hexacetonide: Hexatrione®) to single-injection HA
hylan: Synvisc-One®) in the same injection was compared to hylan
lone, in a prospective randomized study of knee OA with or with-
ut effusion [6]. Results for the association were slightly better
nly during the ﬁrst week, the two groups being comparable at
, 3 and 6 months. Thus associating a corticosteroid to HA tran-
iently improves efﬁcacy but without synergy over time, and does
ot seem justiﬁable as a systematic attitude. Analysis of the sub-
roup with effusion would have been interesting, but data were not
hown.
.1.1.3. Studies versus a reference HA. In France, HA manufacturers
ere recently asked for randomized double-blind trials of non-
nferiority versus a reference substance (Hyalgan® or Synvisc®) by
he Health Authority as a condition for continued coverage. Results
n terms of pain and function, within the limits of this kind of
tudy with only 6 months’ follow-up, indicated non-inferiority for
rthrum® versus Hyalgan®, Structovial® versus Synvisc®, Go-On®
ersus Hyalgan®, Sinovial® versus Synvisc® and Ostenil® versus
ynvisc® [13].
.1.1.4. Response factors. Predictive factors for treatment response
re poorly identiﬁed.
4.1.1.4.1. Type of HA derivative. The type of HA derivative, and
specially its molecular weight, does not appear to be a response
actor according to the clinical studies. Results comparing high-
nd low-MW HA are very discordant, preventing choice between
he HA derivatives available. For single-injection forms:
efﬁcacy at 6 months seems comparable to the 3-injection sched-
ule, at least for hylan GF-20 [23], but long-term (1 year) efﬁcacy
has not been assessed in randomized comparative trials;
injection technique quality certainly plays an important role.
4.1.1.4.2. OA phenotype. OA phenotype plays a role, as we have
een, despite the paucity of studies taking account of patient char-
cteristics: absence of joint effusion, moderate degree of radiologic
oint space narrowing and femorotibial location emerge as predic-
ive factors for good results.
.1.2. Other OA locations
Outside of knee OA, initial hope raised by positive results for HA
n the ﬁrst open studies was dashed by disappointing results from
ecent randomized studies, especially in hip OA. In shoulder and
nkle OA, results have been encouraging. Here we will not go intourgery & Research 101 (2015) S101–S108
the detail of results in small joints, which were moderate in the
thumb and inconclusive for single-injection in hallux rigidus.
4.1.2.1. Hip. HA efﬁcacy is particularly controversial in hip OA. A
2006 meta-analysis [24] of 8 open studies and the ﬁrst 2 controlled
studies found 40–50% efﬁcacy in early forms, and viscosupplemen-
tation was therefore included in international guidelines for the
treatment of hip OA [8].
Three recent controlled studies [25–27], however, sowed doubt
about the efﬁcacy of HA hip injections by ﬁnding no superiority
to placebo. Some poor results may  have been due to poor indica-
tion: one negative trial included advanced hip OA scheduled for hip
replacement, and a majority of hips showed synovitis on ultrasound
[26]. In another study, with ultrasound-guided injection, subgroup
analysis found superiority of HA versus placebo and corticosteroids
in early hip OA with no effusion [25]. A smaller number of injec-
tions in the hip, due to poorer access (just one injection of linear HA
in one trial) may  also explain poorer efﬁcacy [27]. Less restrictive
schedules (1 injection every 3–6 months) are being published [28].
Retrospective analysis of hip replacement rates in a large series
of hip OA with HA injection found that iterative injection enabled
arthroplasty to be postponed [29]. However, HA does not seem
effective in severe hip OA.
In all, HA seems to have some interest in moderate hip OA with-
out effusion, given a sufﬁcient number of injections.
4.1.2.2. Shoulder. HA injection appears effective in shoulder OA.
Two open prospective studies, including one recent one with
hylan GF-20 (Synvisc®), were very encouraging in pure shoulder
OA [30].
An American large-scale controlled study of more than 600
patients with resistant chronic shoulder pain showed 3 or 5 sodium
hyaluronate injections to be effective versus placebo, at 2, 3 and 6
months, only in the shoulder OA subgroup, with or without rotator
cuff tear [31]. In contrast, articular injection in isolated rotator cuff
tear showed no efﬁcacy. Tolerance was  excellent.
A recent Japanese meta-analysis found HA to be more effec-
tive against chronic shoulder pain than NSAIDs, rehabilitation or
corticosteroids with 0.39 (0.26–0.53) pain effect size [32].
4.1.2.3. Ankle. Open studies of 3-injection schedules in moderate-
severe talocrural OA were encouraging [33], but the few controlled
studied showed contradictory results.
A recent meta-analysis reported efﬁcacy in ankle OA if a suf-
ﬁcient number of HA injections were made with dose adapted to
joint capacity [34].
A randomized study suggested efﬁcacy for 3 HA injections 3
weeks after arthroscopic treatment of osteochondral lesions of the
talus [35].
4.2. Results for chondroprotection
Several in vitro studies (cartilage cell culture) suggested HA
has a chondroprotective effect, as did animal trials (OA mod-
els by meniscectomy or anterior cruciate ligament section). Most
reported slower disease progression on the treated side, with cer-
tain variations according to model and animal [36].
There have been few human studies; all concerned knee OA,
with discordant results:• two  old studies with linear HA (Hyalgan®) versus placebo (3
injections every 3 months for 1 year) led to contradictory results
[36];
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a French controlled study showed improvement in arthroscopy
score but not in radiologic impingement in the HA group at 1
year’s follow-up;
a recent randomized series of 78 patients, with 4 cycles of 3
weekly hylan GF-20 (Synvisc®) injections every 6 months for 2
years versus usual treatment, found a signiﬁcant chondropro-
tection effect (cartilage volume on MRI) with reduced annual
condylar cartilage loss at 2 years in the Synvisc® group as com-
pared to controls [37].
A structural impact of HA in frequent-injection schedules is
hus suggested, but requires conﬁrmation; at the present time,
reventive viscosupplementation for chondroprotection cannot be
ormally recommended.
.3. Tolerance
General tolerance for HA injection is excellent and local toler-
nce satisfactory despite usually minor reactions that can be limited
y good injection technique [38].
Caution remains mandatory, and any apparently inﬂammatory
ost-injection effusion requires joint aspiration and systematic
creening for infection.
In reply to the worrying but questionable doubts concerning the
afety of HA raised in Rutges’ meta-analysis [18], a recent literature
eview reiterated the harmlessness of viscosupplementation [39].
.3.1. General tolerance
Rare cases of allergy to avian derivatives (Hyalgan®, Synvisc®)
nd some cases of transient asthenia have been reported.
.3.2. Local tolerance
Post-injection infection is exceptional with HA, with only a few
eported cases although this is probably an underestimation; but
his severe complication is not to be overlooked and mandates pre-
ention in the form of perfect asepsis and patient information on
igns of infection.
The main adverse effect is painful or inﬂammatory local reac-
ion. Frequency is low, at 2–6% in the knee, a little more in other
oints, and treatment efﬁcacy does not seem to be impaired. Pain
s mainly at the injection site and inﬂammation is early, moderate
nd transient; the patient should be alerted to such risk.
More rarely, spectacular acute inﬂammatory reactions with a
seudoseptic aspect may  occur (1–2%). These are unforeseeable and
ainly associated with hylan GF-20, although linear HA may  also be
mplicated. Early onset, 1–24 hours post-injection, is a reassuring
ign of aseptic reaction; in case of the slightest doubt, however, ﬁne-
eedle aspiration and bacteriological analysis should be performed.
There have been a few reports of genuine acute chondro-
alcinosis following HA injection. An open prospective study of
A injection in knee OA with radiologic chondrocalcinosis found
ood injection tolerance with no acute episodes [15]; the patients,
owever, were not in the acute inﬂammatory phase of chondrocal-
inosis.
Exceptional cases of granulomatous reaction have been
escribed, exclusively implicating hylan [38].
. Conclusion
Viscosupplementation remains an attitude of choice as a
isease-modifying treatment for symptomatic OA, especially when
oderate and free of effusion.
It is simple and well tolerated, on condition that the injection
echnique is adapted.
Efﬁcacy is admittedly only moderate, but the rate of responders
s high. It thus enables economy of opioid analgesics and NSAIDs,
[urgery & Research 101 (2015) S101–S108 S107
with a better risk/beneﬁt ratio, and may  allow knee replacement to
be postponed.
There is probably a chondroprotective effect, but this needs con-
ﬁrming before preventive viscosupplementation can be formally
recommended.
The ﬁeld of HA derivatives is evolving, with the development of
single-injection and combined forms. It is hard to choose between
the plethora of products on the market, with their differing char-
acteristics and poorly codiﬁed schedules, especially in joints other
than the knee.
Some points remain unclear, such as predictive factors for treat-
ment response or the role of HA is sports chondropathy.
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